The flavone C-glucoside, vicenin-2, in semi-purified extracts of the leaves of Lychnophora ericoides was quantified in rat plasma samples using a method based on reversed-phase high performance liquid chromatography coupled to tandem mass spectrometry. Vicenin-2 was analyzed on a LiChrospher ® RP18 column using an isocratic mobile phase consisting of a mixture of methanol: water (30:70, v/v) plus 2.0% glacial acetic acid at a flow rate of 0.8 mL min -1 . Genistein was used as internal standard. The mass spectrometer was operated in positive ionization mode and analytes were quantified by multiple reaction monitoring at m/z 595 > 457 for vicenin-2 and m/z 271 > 153 for internal standard. Prior to the analysis, each rat plasma sample was acidified with 200 µL of 50 mmol L -1 acetic acid solution and extracted by solid-phase extraction using a C18 cartridge. The absolute recoveries were reproducible and the coefficients of variation values were lower than 5.2%. The method was linear over the 12.5 -1500 ng mL -1 concentration range and the quantification limit was 12.5 ng mL -1 . Within-day and between-day assay precision and accuracy were studied at three concentration levels (40, 400 and 800 ng mL -1 ) and were lower than 15%. The developed and validated method seems to be suitable for analysis of vicenin-2 in plasma samples obtained from rats that receive a single i.p. dose of 200 mg kg -1 vicenin-2 extract.
Lychnophora (Asteraceae) is a genus of plants which is endemic to Brazil. Several species belonging to this genus are employed in popular use where they have been used for the treatment of wounds, pain and inflammation [1, 2] . Species of Lychnophora have in vivo analgesic and anti-inflammatory properties due to the presence of distinct classes of polar compounds: dicaffeoylquinic acids and vicenin-2 (VIC-2), a C-glucosylflavone [3, 4] .
The absorption rates of dicaffeoylquinic acids and VIC-2 have not been thoroughly investigated. Some authors believe that no absorption of flavonoid glycosides occurs or that their absorption is not significant [5] . For years, the analytical methods employed in pharmacokinetic analysis led to this conclusion, but modern analytical methods, like liquid chromatography-tandem mass spectrometry (LC-MS-MS), have provided evidence that absorption can indeed occur. Most pharmacokinetic studies of flavonoids use O-glucoside or aglycone forms. The flavonoid skeleton defines its presystemic metabolism rate which depends on physiological and enzymatic sensitivity [6] [7] [8] . Flavonoid aglycones are among the metabolites observed after ingestion of O-glucoside flavonoids. This observation can lead to false interpretations about flavonoid absorption [5] . The flavonoid C-glycosides have better stability than flavonoid O-glycosides under physiological and enzymatic conditions [7, 8] . Thus, flavonoid C-glycosides can be good models for studies on flavonoid glycoside absorption and transport across membranes.
Two previous studies presented assays with the flavonoid C-glucoside vitexin-2''-O-rhamnoside (VOR). This flavonoid has one C-C glycosidic bond and one glycosidic O-C bond. In these studies the authors analyzed the samples by using LC-MS-MS and detected intact VOR in rat plasma [9] [10] [11] .
VIC-2 is a flavonoid glycoside which has two glycosidic C-C bonds. There are no data available in the literature about either its absorptivity or bioavailability. Considering also the biological and economic importance of C-flavonoids, we developed an analytical method for analysis of this class in biological samples and demonstrated a possible application in detailed pharmacokinetic studies.
Among several compounds tested as internal standards (IS), genistein was chosen as the most appropriate in the present analysis because it is stable and does not exist endogenously in either rat plasma or exogenously in rat food. Figure 1 (A) shows a typical chromatogram of a drug-free rat plasma sample. No endogenous interfering compounds from plasma were detected at the retention times of VIC-2 and IS. Figure 1 (B-C) shows a chromatogram of a plasma sample from a rat that received an i.p. dose of 200 mg Kg -1 VIC-2 extract. Under the optimized conditions, the SPE recoveries were high and reproducible ( Table 1 ). The method proved to be linear over the concentration range of 12.5-1500 ng mL -1 (y = 0.0028x+0.1639, r 2 = 0.9918). The plasma standard curves in the concentration range of 12.5-1000 ng mL -1 determined on five different days were also linear and had correlation coefficients ≥ 0.9991 and a mean slope of 0.005±0.001. The precision and accuracy of the method were assessed for both within-day (five spiked plasma samples for each concentration on the same day) and between-day (five spiked plasma samples for each concentration for four consecutive days) determinations. Table 2 shows the results for VIC-2, achieved with three concentrations in the evaluation of the precision and accuracy of the method; neither RSDs (relative standard deviations) nor relative errors exceeded 15%, which is in agreement with literature recommendations [13] .The LOD was defined as 10 ng mL -1 . Table 2 also includes the lowest concentration quantified by the validated method (LOQ), which was defined as 12.5 ng mL -1 . In (C), the peak t r =2.59 min corresponds to a concentration of 395.9 ng mL -1 of VIC-2 (45 min post i.p. dose). All rat plasma samples were added of IS (t r =8.06 min) at a concentration of 100 ng mL -1 (B). The conditions for LC-MS-MS analysis are described in the text. The stability test showed no statistically significant difference between freeze-thaw cycles and long-term stabilities of VIC-2 in rat plasma samples under the storage conditions tested (p value ≥ 0.05). However, significant degradation was observed in the short-term room temperature stability test in rat plasma averaging 13 and 29% for VIC-2 at 40 and 800 ng mL -1 , respectively ( Table 3 ). Acidification of plasma samples was proposed by several authors and is very important to prevent the oxidation of phenols [14] [15] [16] . Thus, in this method, addition of 200 µL of 50 mmol L -1 acetic acid solution per mL of rat plasma sample was adopted. These stability results are of great interest for the routine analysis of a large number of samples during kinetic studies. Thus, to avoid degradation, rat plasma samples were acidified to about pH 5 immediately after extraction. The validated LC-MS-MS method was used to perform, for the first time, the determination of VIC-2 in rat plasma. All plasma sample analyses were performed by LC-MS-MS and pharmacokinetic data was determined using a non-compartmental model on three animals. The parameters for areas under the curve (AUC 0-∞ ), elimination constant (k e ), half-life time (t 1/2 ), maximum concentration (C max ), and maximum time (t max ) were also calculated for each animal (Table 4 ).
Preliminary pharmacokinetic analysis was performed using the proposed LC-MS-MS method. Experiments involving a greater number of animals and administration routes must be further performed to confirm the pharmacokinetic parameters for VIC-2. In conclusion, this study describes the development and validation of an LC-MS-MS method for the determination of VIC-2 in rat plasma samples. The method presented here shows good linearity, a low quantification limit, and good precision and accuracy. It should be noted that the assay method was easy and rapid (less than 10 min) to perform, providing good and consistent recoveries for VIC-2 by the SPE procedure. The method is suitable for generating kinetic disposition data following i.p. administration of VIC-2 from crude or semi-purified extract forms of Lychnophora ericoides at a single dose level of 200 mg per kg body weight.
Experimental

Chemicals and reagents:
Enriched fraction of VIC-2 and pure standard were obtained as previously reported [12] . The genistein from Glycine max (soybean) (purity 99.8%, HPLC) used as internal standard was obtained from Sigma (St. Louis, MO, USA). HPLC grade methanol and glacial acetic acid were purchased from J.T. Baker (Phillipsburg, NJ, USA). The water was purified with a Milli-Q system (Millipore, Bedford, MA, USA). SPE cartridges Bakerbond C18, 500 mg/6mL were supplied by J.T. Baker (Phillipsburg, NJ, USA).
Instrumental and chromatographic conditions:
Analyses were carried out using a Shimadzu (Kyoto, Japan) liquid chromatograph consisting of a LC-10AD solvent pump unit, a CTO-10AS column oven and a SLC-10A controller system. Injections were performed manually through a 20 μL loop with a Rheodyne 7125 model injector (Rheodyne, Cotati, CA, USA). Isocratic chromatographic separation was performed at room temperature (24 ± 2ºC) using a LiChrospher ® RP8 column (150 mm × 4.6 mm ID, 5 μm particle size) (Merck, Darmstadt, Germany) and methanol-water (30: 70, v/v) plus 2.0% glacial acetic acid as mobile phase at a flow rate of 0.8 mL min -1 . A C8 guard column (4 mm x 4 mm ID, 5 μm particle size, Merck, Darmstadt, Germany) was used to protect the analytical column. Degassing of mobile phase was achieved by helium sparging before use.
A Valco tee connection was used to split the effluent from the analytical column. A flow rate of approximately 0.2 mL min -1 was directed into the inlet of a Quattro LC triple quadrupole mass spectrometer fitted with a Z-ESI interface (Micromass, Manchester, UK). MS-MS analysis was carried out in the positive ion mode. The source block and desolvation temperatures were kept at 100 and 250ºC, respectively. Nitrogen was used as both drying and nebulizing gas, and argon as collision gas. MS parameters were optimized by direct infusion of VIC-2 and IS solutions prepared in the mobile phase at a flow rate of 20 μL min -1 . The product ion with higher intensity in the acquired spectra was chosen. The transition m/z 596 > 457 was monitored for VIC-2 and m/z 271 > 153 for the IS. Conditions for each transition were tuned to attain higher sensitivity. Summarizing, collision energy was set at 25 eV for VIC-2 and at 40 eV for the IS. The cone and capillary voltages were set for VIC-2 and IS at 30 V and 3.5 kV, respectively. Quantitation was performed by multiple reaction monitoring (MRM) of the protonated molecules ([M+H] + ) and their corresponding product ion with a dwell time of 0.4 s using an IS calibration method with peak height ratios and 1/x 2 weighting. For this purpose, a MassLynx data sampler (Micromass), version 3.0, was employed.
Standard solutions:
Stock standard solutions were prepared at 1 mg mL -1 concentration in methanol. Working solutions of VIC-2 were prepared by appropriate dilution with methanol in the concentration range 100 to 2000 μg mL -1 . The IS solution was prepared at a concentration of 200 μg mL -1 in methanol. All working solutions were stored frozen at -20ºC and protected from direct light and were stable for at least 3 months.
Preparation of calibration standards:
Prior to use, rat plasma samples and standard solutions stored frozen at -20°C were allowed to thaw at room temperature. The calibration curve of VIC-2 was prepared in drug-free rat plasma prior to extraction by adding the required amount of standard solution to obtain final plasma concentrations of 12.5, 25, 50, 100, 250, 500, 750 and 1000 ng mL -1 .
Sample preparation:
Solid-phase extraction (SPE) C18 cartridges (500 mg, 6 mL) were used to extract VIC-2 from rat plasma. The cartridges were activated and conditioned with 2 × 1 mL of methanol and 2 × 1 mL of water. Aliquots of 1.0 mL of rat plasma, acidified with 200 µL of 50 mM acetic acid solution, were added to 25 μL of IS (20 μg mL -1 ) and loaded onto the previously conditioned cartridge (BakerBond, USA) connected to a vacuum manifold system. After washing with 5 × 1 mL of water, the cartridge was dried under vacuum (-30 kPa) for 15 min. The elution of the analytes was carried out with 1 mL of methanol. The eluate was brought to dryness under a gentle stream of compressed air at room temperature. The residue was dissolved in 50 µL of mobile phase and a 20 μL aliquot was injected into the chromatographic system.
Method validation:
The recovery of VIC-2 extracted from the plasma samples spiked with concentrations of 40, 400 and 800 ng mL -1 (n = 3, for each concentration) was determined using calibration curves obtained from the data of analyte which did not undergo the extraction procedure. The absolute recovery was expressed as a percentage of the amount extracted.
The quantification limit (LOQ) was defined as the lowest analyte concentration that could be determined with accuracy and precision below 20% [13] over 5 analytical runs. It was obtained using rat plasma samples (1.0 mL) spiked with 12.5 ng mL -1 of VIC-2. Precision was expressed as relative standard deviation (RSD, %) and accuracy as percent of deviation between the true and the measured value. To assess within-day precision and accuracy, replicate analyses (n = 5) of 1.0 mL of rat plasma spiked with concentrations of 40, 400 and 800 ng mL -1 of VIC-2 were performed. For between-day assays, quintuplicate rat plasma samples of each concentration were analyzed for 4 consecutive days (n = 4) [13] .
Drug-free rat plasma samples were also analyzed to assess the capacity of sample pretreatment in eliminating endogenous interferences.
The stability of VIC-2 was evaluated by testing the influence of freeze (-20ºC) and thaw (23 ± 2ºC) cycles and short-term room temperature. Spiked plasma samples were prepared in triplicate (n = 3) at the low (40 ng mL -1 ) and high concentration (800 ng mL -1 ) of the quality control samples. To perform the freeze-thaw cycle stability test, these samples were stored at -20ºC for 24 h and thawed at room temperature. When completely thawed, the samples were refrozen for 12 h under the same conditions. The freeze-thaw cycle was repeated twice more, and then the samples were analyzed on the third cycle. The short-term room temperature stability test was assessed analyzing samples that were kept on the bench-top for 8 h at room temperature (23 ± 2ºC). After this period, the samples were analyzed. The peak height obtained from the stability tests was compared to the peak height obtained with freshly prepared samples. Student's t test was applied with the level of significance set at p ≤ 0.05.
Method application:
To assess the applicability of the validated method, young healthy male Wistar rats weighting 250±10 g were provided by the Experimental Animal Center of the Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, SP, Brazil. The animals were kept for 3 days before starting experiments in an environmentally controlled room at 24 o C under a 12:12 h cycle (lights on at 6:00) and controlled humidity with free access to standard laboratory food and tap water ad libitum until 12 h before the experiment. The animal experiments were carried out in accordance with the current guidelines for the care of laboratory animals and the ethical guidelines for investigations in conscious animals set by the Ethical Committee of the University of São Paulo, Campus of Ribeirão Preeto, SP, protocol number 07.1.90.53.9.
The VIC-2 extract was dissolved in a mixture of DMSO and water (1:25, v/v) to obtain the extract suspension. After 12 h without ingestion of food or water, groups consisting of 3 rats were injected intraperitoneally (i.p.) with a volume of VIC-2 extract suspension in a similar dose of 200 mg Kg -1 of VIC-2. The animals were decapitated and blood samples were collected in heparinized tubes 15, 30 and 45 min after VIC-2 administration. Plasma fraction samples were separated and 200 µL of 50 mmol L -1 acetic acid solution were added per mL of plasma and were stored at -20ºC until analysis.
